Azacitidine,Magrolimab,Venetoclax
Gilead,Roche,Abbvie
['enhance,(-enhance 3),(-enhance-3),(-enhance3),(-enhanced),(-enahnces),(-enhancem),(-enhancer)', 'magrolimab', 'aza+', 'enhance-2', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'imab ']
another fantastic presentation by reporting on aza/ven/magrolimab in #aml. in the 1l setting, regimen looks promising w/impressive data in tp53 mut. the question is whether ven adds anything or is it all the magro in tp53mut? enhance-2/3 enrolling! #ash22 
Associate Prof of Med @UNC_Lineberger | Oncologist | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | Diehard NYG fan| Views my own